Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases

Figure 1

Therapeutic potential of targeting IL-17-mediated pathway. Several novel strategies in which members of the IL-17 family can be targeted are already in use for preclinical and clinical trials, including inhibitors blocking the differentiation of TH17 cells, IL-17 family cytokines or their cognate receptors-targeted antibodies and small molecule inhibitors blocking transduction of IL-17-mediated signaling in target cells.